Funding for this research was provided by:
Joint Programming Initiative on Antimicrobial Resistance (8th call for networks)
Received: 24 June 2020
Accepted: 22 September 2020
First Online: 26 November 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: MdK received funding from the Innovative Medicines Initiative Joint Undertaking under grant agreements nos. 115523, 115620, and 115737 (Combatting Bacterial Resistance in Europe projects [COMBACTE]), resources of which are composed of financial contribution from the European Union’s 7th Framework Programme (FP7/2007 ± 2013) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) companies’ in kind contribution. CA as a part of EU-JAMRAI (European Union Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections) has received funding from the health programme of the European Union (2014-2020) under grant agreement N°761296.K.O. and R.A.A. was supported by the Cooperative Agreement Number IDSEP160030 from ASPR/BARDA and by awards from Wellcome Trust, the Global AMR Innovation Fund (GAMRIF) funded by the UK Government Department of Health and Social Care (DHSC), the German Federal Ministry of Education and Research (BMBF) and the Bill & Melinda Gates Foundation, as administrated by CARB-X. The contents do not necessarily represent the views of the CARB-X project nor any CARB-X project funder including the governments of the United States (BARDA, NIAID), the United Kingdom (DHSC, GAMRIF), or Germany (BMBF), the Wellcome Trust, or the Bill & Melinda Gates Foundation. KO is also supported by the Social Innovation on Drug Discovery program at Boston University.None of the other Authors have conflicting interests.